FTC’s M&A crack­down; NASH drug gets thumbs down; FDA OKs top­i­cal gene ther­a­py; Com­pa­ny ex­its frus­trate rare dis­ease fam­i­lies; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

June is go­ing to be busy with con­fer­ences, and we have lined up a full slate of pan­els at both AS­CO (vir­tu­al) and BIO (mix of vir­tu­al and live in Boston). Be sure to check them out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER